News

Molbio Diagnostics Limited informed the BSE Limited and National Stock Exchange of India Ltd that KFin Technologies Limited, its Registrar and Share Transfer Agent, has issued a certificate for the quarter ended September 30, 2026, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming that the entire holding of the company was in electronic mode and no rematerialisation requests were received during the period.

Molbio Diagnostics Limited informed the BSE Limited and National Stock Exchange of India Ltd that the trading window for dealing in the company`s securities will be closed for all insiders and designated persons and their immediate relatives from October 01, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended September 30, 2026.

Molbio Diagnostics Limited informed the Bombay Stock Exchange and National Stock Exchange of India that its board of directors approved the re-appointment of M/s K. S. Kamalakara & Co, a Peer-reviewed firm with Firm Reg. No: 000296, as the Cost Auditors of the company for the financial year 2026-27.

Molbio Diagnostics Limited announced that its Board of Directors designated Mr. Darshan Raghunath Karekar as the Compliance Officer of the company under the SEBI (Prohibition of Insider Trading) Regulations, 2015, at a meeting held on August 27, 2026, which commenced at 04.56 P.M. and concluded at 05.08 P.M.